Abstract
Background
Benign prostatic hyperplasia(BPH) is the common male conditions that cause lower urinary tract symptoms disturbing patients. The treatments include pharmacologic, conventional transurethral resection of the prostate(TURP), and minimally invasive. Rezūm as a minimally invasive method has proven effective for BPH, but there is limited comparison with existing treatment modalities. Therefore, we conducted a comparison between Rezūm surgery and the TURP to assess the safety and efficacy of Rezūm.
Methods
Patients hospitalized at the West China Fourth Hospital for BPH were enrolled according to inclusion and exclusion criteria, with 20 undergoing TURP surgery and 20 undergoing Rezūm surgery. After one year of follow-up, we gathered comprehensive patient demographics and perioperative data and conducted postoperative evaluations including the International Prostate Symptom Score (IPSS) and Quality of Life (QOL) scores.
Results
After one year of follow-up, IPSS scores decreased by 57.35% in the TURP group and by 61.50% in the Rezūm group, respectively (p < 0.05). Similarly, QOL scores decreased by 63.12% and 63.92% in each respective group (p < 0.05). Notably, the Rezūm group exhibited significantly shorter operative times, reduced operative blood loss, and shorter hospital stays compared to the TURP group (p < 0.0001, p < 0.0001, p = 0.025). Three days post-surgery, the Rezūm group reported lower Numeric Rating Scale (NRS) scores compared to the TURP group (p < 0.0001), and experienced a shorter duration of hematuria (p = 0.023).
Conclusions
Rezūm enhanced the efficacy of BPH treatment at the one-year postoperative mark, yielding outcomes on par with those of TURP. Furthermore, Rezūm showcased notable advantages during the perioperative phase.